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Abstract
The atopic march is defined as the progression of atopic diseases, generally during childhood, such as atopic dermatitis, asthma, allergic 
rhinitis and food allergies. The main risk factors for developing these atopic diseases include genetics, aeroallergens, food allergens, late 
food introduction to the infant, and living in developing countries. The immunologic contributors to this problem include the Th2 response, 
epigenetics, and lack of certain factors like thymic stromal lymphopoietin (TSLP) and filaggrin. As a whole, the therapeutic approach has 
been changing during recent years because of the discovery of new factors involved in this problem.  This article explains the definition of 
atopic march, the immunological pathway, clinical features, epidemiology and therapeutic approaches to create a context for the broader 
understanding of this important condition.
Keywords: Atopic dermatitis; asthma; allergy; atopy; Th2 response; atopic march (Source: MeSH, NLM) 
About the author: Juan F. 
Salazar-Espinosa is cu-
rrently a 3rd year medical 
student of University of 
Caldas, Manizales, Colom-
bia of a six year program. 
He is also the treasurer 
of the Medical Student’s 
Scientific Association of 
Universidad de Caldas 
(ACEMCAL).
Submission: Mar 18, 2014
Acceptance: Aug 22, 2014
Process: peer-reviewed
Correspondence:
Juan F. Salazar-Espinosa
Address: Calle 65 Nº 26 - 10, Manizalez, Colombia.
Email: jfsehc1995@hotmail.com
Introduction
Atopic march is an epidemiological phenomenon involving ato-
pic diseases and describes the process by which some atopic 
diseases interrelate through a patient’s life. These atopic di-
seases include asthma, atopic dermatitis (AD), allergic rhinitis, 
and food allergies. The common progression of these diseases 
is from atopic dermatitis to asthma and then allergic rhinitis; 
this is not, however, the only way that this condition progres-
ses. The atopic march has some associated risk factors that 
have been described in epidemiological studies from different 
countries. There exist, however, some differences in the disea-
se epidemiology depending on the socioeconomic status of the 
country studied.1
The pathogenesis of the atopic processes share a common sys-
temic Th2 response and epigenetic factors. Related to Th2 res-
ponse are other immunological factors like filaggrin deficiency 
and thymic stromal lymphopoietin (TSLP) overexpression which 
have been demonstrated in mouse models and serve as thera-
peutic targets.2 These exist in addition to the ratio between his-
tone acetyl transferase (HAT) and histone deactetylase (HDAC) 
as the most important epigenetic factors involved in allergies.3 
The therapeutic approach has multiple pharmacological op-
tions, including subcutaneous and sublingual immunotherapy, 
prebiotics, probiotics and, most recently, anti-IgE monoclonal 
antibodies. The multitude of therapeutic approaches seen in 
atopic march may be explained by the observation that there 
are different preferences for various treatments among diffe-
rent medical specialties.4
Search Strategy and Selection Criteria
A literature search was performed using MEDLINE MeSH ter-
ms “eczema”, “asthma”, “food allergy” and “allergic rhinitis” 
where each term was combined with “atopic march” using the 
PubMed search builder. A total of 177 articles were found.  Fo-
llowing filtering by author criteria (publication within last 20 
years, English language, and the existence of a relation be-
tween at least two atopic diseases), 32 articles remained and 
an additional 22 articles were retrieved from references. This 
review follows the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) Statement.5
Immunological Pathway 
The first step in atopic march pathogenesis is allergen expo-
sure or the first sensitization episode in a patient’s life, lea-
ding to the activation of the epithelial cell triggers and the 
release of TSLP and tumor necrosis factor alpha (TNF-?). These 
are chemotactic factors for dendritic cells, which induce the 
expression of adhesion molecules at the endothelium.6 Den-
dritic cells internalize the allergen through their high affinity 
IgE receptors (Fc?RI) and migrate and mediate the naïve T cell 
activation in Th1 cells, which releases interleukin-2 (IL-2) and 
interferon-gamma (IFN-?), and Th2 cells, which releases IL-4, in 
the lymph nodes. Following this is a process called scratch-ru-
bbing cycle where a skin barrier dysfunction (filaggrin muta-
tions) leads to a decrease in Th1 response and an increase in 
Th2 response with the release of IL-5 and IL-13. This triggers 
the increase in eosinophilic infiltration with an immunoglobu-
lin E (IgE) hyperproduction. The Th2 response enhances the 
allergen response in the nasal and bronchial mucosa, leading 
to eosinophil infiltration and IgE hypersecretion in addition to 
the mast cell proliferation, epithelial cell activation, mucus 
hypersecretion, and smooth muscle proliferation observed in 
asthma.7,8
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Filaggrin is a protein produced in the stratum corneum of the 
epidermis that plays an essential role in the formation of the 
protective skin barrier by the prevention of water loss and 
entry of microbes into the inner layers of the skin. The main 
mechanism that involves filaggrin in the allergic disease pa-
thogenesis is the enhancement of the Th2 systemic response, 
which leads to the susceptibility of skin, bronchial, nasal, and 
gastrointestinal epithelia to the development of atopic disea-
ses, especially atopic dermatitis and asthma.9 Importantly, it 
has been discovered that the maintenance and repair of the 
epidermal barrier in infants with AD may prevent the subse-
quent development of asthma.10
The TSLP is an IL-7-like interleukin which is produced in the 
skin, gut, lungs and thymus and contributes to the activation 
of dendritic cells without the allergen molecule, the predo-
mination of Th2 differentiation, and the upregulation of this 
response by the mast cells in the nasal epithelium, leading 
to the development of allergic rhinitis.11 Figure 1 shows the 
process involved in the generation of atopic march and some 
of the factors that may contribute to the development of atopic 
diseases.
Takai et al., suggested that environment, infection, and/or 
self-derived toll-like receptor ligands contribute to the initia-
tion and/or amplification of Th2-type skin inflammation, inclu-
ding atopic dermatitis, through the induction of TSLP expres-
sion in keratinocytes. This finding is helpful for understanding 
the role of the gene–environment interaction relevant to aller-
gic diseases.12 
One of the main factors in the epigenetics of the atopic march 
is GATA-3, which is activated by T-cell receptor (TCR) and IL-4 
receptor activation and maintains its own expression throu-
gh positive feedback. GATA-3 induces permissive histone and 
chromatin changes at the Th2 Locus Control Region (LCR) which 
enhances the Th2 response and suppresses the Th1 respon-
se against the allergens. Another important factor is FFOXP3, 
which regulates the T regulator cell action by promotiing the 
binding of demethylation factors and the consequent lack of 
toleration to self and exogenous antigens.3
Mouse Models in Atopic March 
Zhang et al., carried out investigations in which they injected 
mice with intra-peritoneal ovalbumin and measured the TSLP 
produced by keratinocytes. TSLP is the mediator of the skin 
inflammation triggered by an allergen and consequent sensi-
tization. Additionally, another mouse model demonstrates a 
relation between high skin keratinocyte-derived TSLP, high TSLP 
serum levels and the upregulated epicutaneous sensitization, 
and aggravated allergic asthma generated upon allergen cha-
llenge in airways.13,14 However, Demrhi et al., demonstrated 
that during the first 3 years of life, the plasma circulating TSLP 
of children with eczema, allergen sensitization, or wheezing 
was not statistically associated with the manifestation of these 
symptoms.2 The TSLP is implicated in mouse models for the 
development of atopic diseases. This supports the utilization 
of TSLP inhibition as a proposed therapeutic option to prevent 
or limit allergen sensitization and thus halt the progress of the 
atopic march.15
Clinical Features
Atopic Dermatitis
There are three established phases in the progression of AD: 
an infantile phase (from birth to 2 years of age), a childhood 
phase (2 years to puberty) and the adult phase (from puber-
ty to the adulthood). The first manifestations correspond to 
erythematous papules and vesicles that typically begin on the 
face and are intensely pruritic. There is also edema of affected 
areas, leading to oozing and crusting. The childhood phase 
of AD additionally presents with lichenified papules and pla-
ques, representing a more chronic disease. Lymphadenopathy 
might be a prominent feature in affected children. Although 
the disease sometimes tends to self-resolve, there is an adult 
phase of AD which predominantly involves the flexural folds, 
the face and neck, the upper arms and back, and the dorsa 
of the hands, feet, fingers, and toes. Weeping, crusting, and 
exudation might occur, usually as a result of superimposed 
Staphylococcal infection.10
Asthma, Allergic Rhinitis and Food Allergy
A wide array of risk and protective factors including hygie-
ne, infections, outdoor and indoor air pollution, allergen ex-
posure, breast-feeding practices, genetic factors, nutrition, 
and obesity play a multifaceted role in shaping the observed 
worldwide trends of respiratory allergies.16 Some of these pa-
tients never present with any clinical symptoms throughout 
their lives, although airway hyperresponsiveness, shortness of 
Figure 1. A proposed pathway to explain the atopic march from childhood eczema to the development of asthma and allergic rhinitis.4
Source: Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014 Jan;69(1):17-27. Reprinted 
with permission from John Wiley and Sons.
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breath, wheezing which causes chronic airflow limitation, and 
decreased lung function are common. Examinations of these 
patients reveal low forced expiratory volume in 1 second (FEV1) 
together with an increased eosinophil and Th2 infiltration in 
bronchial tissue. An Indian study shows that fractional exhaled 
nitric oxide (FeNO) is a marker of lower airway inflammation; 
therefore, significantly higher FeNO levels in atopic allergic rhi-
nitis patients may predict the onset of asthma.17 For allergic 
rhinitis, there are four main symptoms: watery rhinorrhea, 
nasal obstruction, nasal itching, and sneezing.18 Like asthma, 
allergic rhinitis could be classified as mild or moderate-severe 
based on severity.19-21
Food allergy is known to be one part of this atopic process and 
its incidence tends to be higher at 2 years of life.22 A clinica-
lly relevant event is cow milk allergy, which is proposed as a 
risk factor for the development of asthma, rhinoconjuctivitis 
and eczema.23 Food allergy is clinically well characterized by 
urticaria, angioedema, vomiting or anaphylaxis. These clinical 
manifestations are present within two hours following the food 
ingestion. There are some foods that mediate this disease like 
peanuts, cow milk, and eggs. Besides these symptoms other 
clinical manifestations include a scratchy throat, hives anywhe-
re on the body, swelling of the eyelids, face, or tongue, nausea, 
cramps, vomiting, diarrhea, nasal congestion, and shortness 
of breath or wheezing due to the exposure to a hapten of the 
food.24 A controversial dilemma, which began in the 1970s and 
remains unresolved, includes whether the introduction of food 
antigens into the diet either early or later in life has any effect 
on the development of food allergy, atopy or allergic asthma. 
This is explained by the antigens present in the food (cow milk) 
which are captured by the Peyer patches and generate a Th1 
response in healthy children.25,26 Some studies concluded that 
the early food introduction and six months breastfeeding after 
birth are poor prognostic factors and predispose the infants to 
the development of food allergy.27 However, a population-ba-
sed prospective cohort study using 3781 children performed 
in 2013 established that long term breastfeeding and the early 
introduction (with specific timing) of wheat, rye, oats, barley 
cereals, ﬁsh, and eggs is preferred in that it protects  against 
the development of asthma and allergic rhinitis from a few 
months following birth to the age of five. This finding suggests 
a potential conflicting effect of breastfeeding on different as-
thma phenotypes.28
Epidemiology
There are three established progressive pathways in this pro-
cess: (1) atopic dermatitis to asthma and allergic rhinitis, (2) 
asthma to atopic dermatitis, and (3) asthma to rhinitis without 
the presence of atopic dermatitis. Food allergy is an associa-
ted risk factor in the development of these three conditions, 
and for this reason it can be found in any phase of the atopic 
march. However, a reverse atopic march has been proposed, 
with patients developing asthma first with the later appearan-
ce of atopic dermatitis. This is demonstrated in a prospective 
study that followed nearly 700 children aged six to nine years 
with asthma alone for nine years. Twenty percent of the chil-
dren developed atopic dermatitis at the end of nine years.29
Atopic dermatitis has a prevalence that ranges from 7% to 30% 
in children and from 2% to 10% in adults.30 AD and food aller-
gies have the highest incidence in the first two years of life. 
Sensitization to inhalant allergens is rare at that time of life. 
In later childhood, the prevalence of AD and food allergies de-
creases while the prevalence of asthma, allergic rhinitis, and 
sensitization to inhalant allergens rises.31 Shen et al., followed 
a birth cohort for seven years and classified the eczema into 
preschool and late-onset and examined the correlation be-
tween the development of asthma and allergic rhinitis. Results 
showed that the 36 month old group (late-onset group) had the 
highest risk for developing asthma or allergic rhinitis five years 
later. This indicates that it is necessary to evaluate the asso-
ciated risk factors at the first presentation of atopic disease in 
order to predict its progression in subsequent years.32
A longitudinal study of a prospective birth cohort of 620 chil-
dren described a higher prevalence of atopic march in boys 
than girls by a mechanism that remains unknown.33 Higher 
body mass index (BMI) is a risk factor for atopy, wheezing, and 
cough in girls only.34 However, higher BMI is not a risk factor for 
asthma or airway hyperresponsiveness in either boys or girls. 
As the atopic march is a disease of interrelation, the etiology 
is not the same for all components. In fact, it is described that 
parents with asthma give birth to children with four times the 
odds of developing food allergy.35 The food allergy is associated 
with six times the odds of developing asthma compared to 
patients without any food allergy.36,37
It is believed that developed countries have reached a plateau 
in the incidence of asthma while in developing countries the 
incidence of these diseases is still increasing.16 Van der Hulst et 
al., conducted a systematic review which assessed the risk of 
developing asthma in children with atopic eczema during the 
first four years of life and found that the prevalence of asthma 
at the age of six years in eczema cohort studies was 35.8% for 
inpatients and 29.5% for a combined group of inpatients and 
outpatients.38 A Norway study, with 4780 children divided into 
two groups depending on whether they were followed from two 
years old to six years old (n=2192) or not followed (n=2588). 
Among children with follow-up data at six years, the prevalen-
ce of eczema, asthma, and wheezing at two years was 17.8%, 
6.5% and 25.3%, respectively. Among children with follow-up 
data at six years, the odds ratio between eczema at two years 
and current asthma at six years was 1.95. When the age of 
onset for eczema was included in the model, an onset before 
four months of age was significantly associated with asthma at 
six years (OR= 4.51).39  
Meanwhile, in middle-income countries, a study conducted 
during the 2009-2010 period in Colombia collected informa-
tion from 5,978 patients and analyzed three principal atopic 
diseases: allergic rhinitis, atopic eczema and asthma. It was 
discovered that 12% of the patients had asthma, 32% had aller-
gic rhinitis and 14% had atopic eczema and demonstrated an 
increased presentation of symptoms characteristic of these 
conditions.40 In Taiwan, Hwang CY et al., collected longitudinal 
cohort information through the medical institution databases 
that followed patients for eight years. Overall, 66,446 patients 
were diagnosed with atopic dermatitis and 49.8% of them had 
concomitant allergic rhinitis and/or asthma. The overall 8-year 
prevalence of atopic dermatitis, allergic rhinitis, and asthma 
was 6.7%, 26.3% and 11.9%, respectively.41 In addition, Waked 
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et al., administered standardized written questionnaires to 5- 
to 12-year-old students at 22 schools. In total, 3,909 individuals 
were analyzed. The prevalence of diagnosed asthma (4.8%) was 
low, while the prevalence of allergic rhinitis was 21.2% and that 
of eczema was 11.8%. Marked variations and differences were 
found across the governorates in Lebanon, with the lowest pre-
valence of diagnosed asthma found in Bekaa (1.8%) and the 
highest prevalence in Beirut (11.6%).42 The differences in the 
prevalence of atopic diseases between developing and deve-
loped countries likely reflect the differences in the extent of 
urbanization, industrialization, life style, latitude, and disease 
severity. Other possible factors, such as socioeconomic status 
or ethnic group, may also contribute to this variation.
Therapeutic Approaches 
Gordon BR et al., suggested that it is possible to interrupt the 
atopic march to prevent allergy, especially asthma, with three 
possible interventions: (1) supplements of dietary probiotics, 
(2) exclusive breast feeding during the first few months of life, 
which provides protection from the development of allergies 
through the high transforming growth factor beta (TGF-ß) levels 
in breast milk, and (3) treatment with inhalant allergen immu-
notherapy by either subcutaneous or sublingual immunothera-
py, both of which decrease the risk of progression to asthma 
and allergic rhinitis. From current data, if these strategies were 
widely employed, there would likely be a substantial reduction 
in future asthma cases.43 This is supported by the 2013 PRACTA-
LL trial, which has established a subcutaneous immunotherapy 
and a sublingual immunotherapy for allergic asthma and rhini-
tis based on scores given for symptom reduction, improvement 
in quality of life, and the induction of favorable changes in spe-
cific immunologic markers.44 In a randomized controlled trial, 
Passalacqua et al., found  immunotherapy for allergic rhinitis 
to be a preventive factor for asthma development due to the 
impairment of new sensitizations.21
Anti-IgE treatment with omalizumab is another therapeutic 
option used for rhinitis where its mechanism of action is by 
specifically binding to IgE with the consequent interruption in 
the allergic response. New information suggests that the com-
bination of immunotherapy with omalizumab is a good strategy 
to treat allergic rhinitis.45 However, when the monoclonal anti-
body XmAb7195, human leukocyte-engrafted mouse like omali-
zumab, was administered, it selectively reduced serum human 
IgE levels and was much more effective than omalizumab in 
suppressing IgE levels by dual pathways involving IgE neutra-
lization and a CD32b-dependent inhibition of the formation of 
IgE-secreting plasma cells. This demonstrates new advances in 
therapeutic approaches by inhibiting one of the main factors in 
the development of atopic diseases (i.e. IgE).46
Prebiotics, probiotics and breast feeding balance the “Th2 
bias”, thus improving intestinal processing of antigens inges-
ted in the diet and reducing intestinal inflammation and IgE 
production by increasing the uptake of antigens by Peyer’s 
patches. This prevents the development of a Th2-exaggerated 
immune response which would lead to the systemic sensitiza-
tion and major enhancement and distribution to tissues like 
bronchial tissue.47 Breastfeeding is recommended to be com-
plemented with probiotics because it increases the number of 
of immunoglobulin secretor cells, which is one of the main 
factors involved in protection against atopic problems.48 It is 
theorized that probiotics act at the Clostridium/Bifidobacterium 
ratio by increasing the Bifidobacterium populations.49 Moreo-
ver, according to Vitaliti et al., the use of probiotics induces 
the enhancement of regulatory cell responses to produce more 
anti-inflammatory cytokines which may decrease the likelihood 
of the development of allergies.50 In 62 mother–infant pairs, 
Lactobacillus rhamnosus GG administered during the four wee-
ks before the infant’s birth and during breast feeding (first 
three months) increased the immuno-protective potential of 
breast milk, as assessed by the enhancement of anti-inflam-
matory TGF-ß2 in the milk of the mothers receiving probiotics 
vs. placebo.51 Furthermore, the probiotics are considered to be 
the main factors involved in the prevention of atopic march.52 
Prebiotics are nondigestible food products (most commonly 
oligosaccharides) that stimulate the growth or activity of Bi-
fidobacteria and other “friendly” bacteria in the colon. Howe-
ver, further research is needed before routine use of prebiotics 
can be recommended for prevention of allergy in formula fed 
infants. It is unclear whether the use of prebiotic should be 
restricted to infants at high risk of allergy or whether they 
may have an effect in low risk populations or on other allergic 
diseases including asthma.53
 
Conclusion
New information constantly expands our understanding of 
allergen-induced diseases; this information is reflected in 
epidemiological studies which demonstrate a non-linear de-
velopment and relationship of the various components of the 
atopic march. The atopic march should be understood as an 
immunological imbalance in Th2 responses together with fac-
tors like the TSLP, lack of filaggrin, and epigenetics (FOXP3 and 
GATA-3). The epidemiologic data tends to be in accordance with 
data obtained using mouse models, which provide insights to 
the development of additional epidemiologic studies. In regard 
to the therapeutic approach, atopic march should always be 
understood as a multiple-disease problem and not simply as 
a single atopic disease. The monoclonal antibodies, sublingual 
therapy, immunotherapy, prebiotics and probiotics are proving 
to be promising therapies which need further investigation to 
demonstrate their action against the immunological factors in-
volved in this disease.
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